Lantus and Injection site induration - a phase IV clinical study of FDA data

Summary:

Injection site induration is reported as a side effect among people who take Lantus (insulin glargine recombinant), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Humalog, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Injection site induration when taking Lantus. It is created by eHealthMe based on reports of 190,478 people who have side effects when taking Lantus from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Injection site induration?

Injection site induration is found to be associated with 556 drugs and 627 conditions by eHealthMe. Check the latest studies of Injection site induration.

On Jul, 28, 2026

190,478 people reported to have side effects when taking Lantus.
Among them, 197 people (0.1%) have Injection site induration.

Could Lantus cause Injection site induration?

Among these 197 people:

How long have people been on Lantus when they have Injection site induration? *

Click here to view more results

What is the gender of people who have Injection site induration when taking Lantus? *

Click here to view

What is the age of people who have Injection site induration when taking Lantus? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and have Injection site induration?

- Check whether Injection site induration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lantus:

Lantus (191,782 reports)

Injection site induration treatments and more:

Injection site induration (13,655 reports)

How severe was Injection site induration and when was it recovered:

Injection site induration in Lantus

Expand to all the drugs that have ingredients of insulin glargine recombinant:

Injection site induration and drugs with ingredients of insulin glargine recombinant (218 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site induration:

Injection site induration (556 drugs)

Browse all the conditions that are associated with Injection site induration:

Injection site induration (627 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.